Comparative efficacy of monoclonal antibodies that bind to different epitopes of the 2009 pandemic H1N1 influenza virus neuraminidase

Journal of Virology

Volumn 90, Issue 1, 2016, Pages 117-128

  Jiang, Lianlian ^a   Fantoni, Giovanna ^a   Couzens, Laura ^a   Gao, Jin ^a   Plant, Ewan ^a   Ye, Zhiping ^a   Eichelberger, Maryna C ^a   Wan, Hongquan ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1H5; MONOCLONAL ANTIBODY 4E9; MONOCLONAL ANTIBODY CD6; MONOCLONAL ANTIBODY HF5; UNCLASSIFIED DRUG; VIRUS SIALIDASE; NA PROTEIN, INFLUENZA A VIRUS; PROTEIN BINDING; SIALIDASE; VIRAL PROTEIN; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); LOW DRUG DOSE; MICROBIAL ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS INHIBITION; VIRUS MUTANT; VIRUS TRANSMISSION; ANIMAL; DBA MOUSE; DISEASE MODEL; ENZYMOLOGY; IMMUNOLOGY; ISOLATION AND PURIFICATION; ORTHOMYXOVIRIDAE INFECTIONS; PASSIVE IMMUNIZATION; PHYSIOLOGY; SURVIVAL ANALYSIS; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE, INBRED DBA; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN BINDING; SURVIVAL ANALYSIS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84953857646     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01756-15     Document Type: Article

References (39)

1. Kilbourne ED, Johansson BE, Grajower B. 1990. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci U S A 87:786-790. http://dx.doi.org/10.1073/pnas.87.2.786.
2. Air GM. 2012. Influenza neuraminidase. Influenza Other Respir Viruses 6:245-256. http://dx.doi.org/10.1111/j.1750-2659.2011.00304.x.
3. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. 2004. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78:12665-12667. http://dx.doi.org/10.1128/JVI.78.22.12665-12667.2004.
4. Wagner R, WolffT, Herwig A, Pleschka S, Klenk HD. 2000. Interde-pendence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J Virol 74:6316-6323. http://dx.doi.org/10.1128/JVI.74.14.6316-6323.2000.
5. Palese P, Compans RW. 1976. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 33:159-163. http://dx.doi.org/10.1099/0022-1317-33-1-159.
6. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52:3284-3292. http://dx.doi.org/10.1128/AAC.00555-08.
7. Okomo-Adhiambo M, Fry AM, Su S, Nguyen HT, Elal AA, Negron E, Hand J, Garten RJ, Barnes J, Xiyan X, Villanueva JM, Gubareva LV. 2015. Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14. Emerg Infect Dis 21:136-141. http://dx.doi.org/10.3201/eid2101.141006.
8. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Givney RC, Xue L, Maurer-Stroh S, Dwyer DE, Wang B, Smith DW, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durrheim D, Barr IG. 2012. Characteristics of a widespread community cluster of H275Y oseltamivirresistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 206:148-157. http://dx.doi.org/10.1093/infdis/jis337.
9. Eichelberger MC, Wan H. 2015. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol 386:275-299. http://dx.doi.org/10.1007/82_2014_398.
10. Murphy BR, Kasel JA, Chanock RM. 1972. Association of serum antineuraminidase antibody with resistance to influenza in man. NEngl J Med 286:1329-1332. http://dx.doi.org/10.1056/NEJM197206222862502.
11. Ogra PL, Chow T, Beutner KR, Rubi E, Strussenberg J, DeMello S, Rizzone C. 1977. Clinical and immunologic evaluation of neuraminidasespecific influenza A virus vaccine in humans. J Infect Dis 135:499-506. http://dx.doi.org/10.1093/infdis/135.4.499.
12. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. 1974. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 129:411-420. http://dx.doi.org/10.1093/infdis/129.4.411.
13. Kilbourne ED, Laver WG, Schulman JL, Webster RG. 1968. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 2:281-288.
14. Johansson BE, Grajower B, Kilbourne ED. 1993. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 11:1037-1039. http://dx.doi.org/10.1016/0264-410X(93)90130-P.
15. Brett IC, Johansson BE. 2005. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 339:273-280. http://dx.doi.org/10.1016/j.virol.2005.06.006.
16. Monto AS, Kendal AP. 1973. Effect of neuraminidase antibody on Hong Kong influenza. Lancet i:623-625.
17. Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ. 2011. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS One 6:e26335. http://dx.doi.org/10.1371/journal.pone.0026335.
18. Xu X, Cox NJ, Bender CA, Regnery HL, Shaw MW. 1996. Genetic variation in neuraminidase genes of influenza A (H3N2) viruses. Virology 224:175-183. http://dx.doi.org/10.1006/viro.1996.0519.
19. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4:e59. http://dx.doi.org/10.1371/journal.pmed.0040059.
20. Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, Cox RJ, Palese P, Krammer F. 2015. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio 6:e02556. http://dx.doi.org/10.1128/mBio.02556-14.
21. Webster RG, Brown LE, Laver WG. 1984. Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. Virology 135:30-42. http://dx.doi.org/10.1016/0042-6822(84)90114-4.
22. Chen Z, Kim L, Subbarao K, Jin H. 2012. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 30:2516-2522. http://dx.doi.org/10.1016/j.vaccine.2012.01.090.
23. Easterbrook JD, Schwartzman LM, Gao J, Kash JC, Morens DM, Couzens L, Wan H, Eichelberger MC, Taubenberger JK. 2012. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432:39-44. http://dx.doi.org/10.1016/j.virol.2012.06.003.
24. Marcelin G, Sandbulte MR, Webby RJ. 2012. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol 22:267-279. http://dx.doi.org/10.1002/rmv.1713.
25. Doyle TM, Jaentschke B, Van Domselaar G, Hashem AM, Farnsworth A, Forbes NE, Li CG, Wang JZ, He RT, Brown EG, Li XG. 2013. The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication. J Biol Chem 288:18283-18289. http://dx.doi.org/10.1074/jbc. M113.468884.
26. Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X. 2013. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res 100:567-574. http://dx.doi.org/10.1016/j.antiviral.2013.09.018.
27. Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC. 2013. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol 87:9290-9300. http://dx.doi.org/10.1128/JVI.01203-13.
28. Wan H, Yang H, Shore DA, Garten RJ, Couzens L, Gao J, Jiang L, Carney PJ, Villanueva J, Stevens J, Eichelberger MC. 2015. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers. Nat Commun 6:6114. http://dx.doi.org/10.1038/ncomms7114.
29. Boon AC, deBeauchamp J, Krauss S, Rubrum A, Webb AD, Webster RG, McElhaney J, Webby RJ. 2010. Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. J Virol 84:7662-7667. http://dx.doi.org/10.1128/JVI.02444-09.
30. Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K, Roseby S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J, Manojkumar R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E, Agius C, Camuglia S, Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O, Xie H, Li X, Lin Z, Ye Z, Chen LM, O'Neill E, Balish A, Lipatov AS, Guo Z, Isakova I, Davis CT, Rivailler P, Gustin KM, Belser JA, Maines TR, Tumpey TM, Xu X, Katz JM, Klimov A, Cox NJ, Donis RO. 2011. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 29:1836-1843. http://dx.doi.org/10.1016/j.vaccine.2010.12.044.
31. Sandbulte MR, Westgeest KB, Gao J, Xu X, Klimov AI, Russell CA, Burke DF, Smith DJ, Fouchier RA, Eichelberger MC. 2011. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci U S A 108:20748-20753. http://dx.doi.org/10.1073/pnas.1113801108.
32. Plant EP, Ye Z. 2015. Chimeric neuraminidase and mutant PB1 gene constellation improves growth and yield of H5N1 vaccine candidate virus. J Gen Virol 96:752-755. http://dx.doi.org/10.1099/jgv.0.000025.
33. Couzens L, Gao J, Westgeest K, Sandbulte M, Lugovtsev V, Fouchier R, Eichelberger M. 2014. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J Virol Methods 210C:7-14. http://dx.doi.org/10.1016/j.jviromet.2014.09.003.
34. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. 2001. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146:2275-2289. http://dx.doi.org/10.1007/s007050170002.
35. Air GM, Els MC, Brown LE, Laver WG, Webster RG. 1985. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. Virology 145:237-248. http://dx.doi.org/10.1016/0042-6822(85)90157-6.
36. Varghese JN, Laver WG, Colman PM. 1983. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 303: 35-40. http://dx.doi.org/10.1038/303035a0.
37. Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H, Odagiri T, Tashiro M. 2014. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill 19(1): pii=20666. http://dx.doi.org/10.2807/1560-7917.ES2014.19.1.20666.
38. Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, Sato H, Odagiri T, Kawaoka Y, Tashiro M. 2015. Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan. Antimicrob Agents Chemother 59:2607-2617. http://dx.doi.org/10.1128/AAC.04836-14.
39. Air GM, Laver WG, Webster RG. 1990. Mechanism of antigenic variation in an individual epitope on influenza virus N9 neuraminidase. J Virol 64:5797-5803.